Mouse models and proteomics tackling acute lymphoblastic leukaemia

Assessing iron overload and toxicity

What clinicians believe they said and what patients believe they heard

New drugs for relapsed and refractory Hodgkin's lymphoma

How malignant cells in patients with CLL escape T-cell recognition

Reducing radiotherapy for Hodgkin's lymphoma while maintaining the highest cure rate

Impressive results with a bispecific antibody for ALL

Phase 1-2 results for oral proteasome inhibitor MLN9708 for multiple myeloma (Spanish)

Early phase trial of ibrutinib for chronic lymphocytic leukaemia

Acute Lymphocytic Leukemia: impressive results with a bispecific antibody in patients with refractory disease

How malignant cells in patients with CLL escape T-cell recognition

Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma